Logo

GeneQuine Biotherapeutics GmbH

Company

Primary tabs

About your organization / profile

GeneQuine develops next generation gene therapy for musculoskeletal diseases with a potentially disease-modifying lead candidate for osteoarthritis.

In 2017, GeneQuine sold its (then-) lead program for osteoarthritis to Flexion Therapeutics Inc. for up to $64 million. 

GeneQuine is currently raising a series A of €16 million to take its second gene therapy drug candidate for osteoarthritis to the clinic, to start a development program for degenerative disc disease, and to expand its lab.

Network (0)

There are no organizations in the network.